The abstract is read at the publisher; the summary is JClub's.
High midkine (MDK) expression in clear cell renal cell carcinoma (ccRCC) is linked to advanced stage, aggressive histology, and worse survival, defining a Treg-enriched immune-evasive phenotype.
- Why it matters: Tregs drive immunosuppression in ccRCC, but the tumor-intrinsic epithelial signals that activate Tregs and enable immune escape are not well defined, limiting biomarker and target discovery.
- What they did: Single-cell RNA-seq epithelial–Treg communication was mapped with CellChat, then MDK was prioritized by survival analyses and validated across bulk datasets, immunotherapy cohorts, and a prospective institutional ccRCC cohort. Spatial multiplex immunofluorescence assessed co-localization with forkhead box P3 + Tregs, and functional effects were tested in vitro and in a syngeneic mouse model treated with anti-PD-1.
- The result: MDK upregulation predicts poorer outcomes with PD-1 monotherapy and tyrosine kinase inhibitor monotherapy, shows an adverse trend with immune checkpoint inhibitor-based anti-angiogenic combinations, and is associated with reduced tumor control during PD-1 blockade in vivo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.